Health Care & Life Sciences » Biotechnology | VioQuest Pharmaceuticals Inc.

VioQuest Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Sales/Revenue
669.00
1,485.10
-
-
-
Cost of Goods Sold (COGS) incl. D&A
884.20
1,016.70
1.60
6.30
8.90
Gross Income
215.10
468.50
1.60
6.30
8.90
SG&A Expense
1,814.50
4,155.30
2,229.40
5,275.00
8,770.40
Unusual Expense
-
375.00
8,165.20
-
963.20
Interest Expense
2.80
-
-
16.30
1,200.30
Pretax Income
2,018.40
4,023.60
10,353.90
5,175.60
10,868.70
Income Tax
-
-
-
-
240.70
Consolidated Net Income
2,018.40
4,023.60
10,353.90
5,175.60
10,628.00
Net Income
2,018.40
4,023.60
10,353.90
5,175.60
10,628.00
Net Income After Extraordinaries
2,018.40
4,023.60
7,873.10
2,080.00
10,364.40
Net Income Available to Common
2,018.40
4,023.60
10,353.90
5,175.60
10,628.00
EPS (Basic)
1.60
2.40
5.80
2.10
2.30
Basic Shares Outstanding
1,247.70
1,710.10
2,203.40
3,978.70
4,672.20
EPS (Diluted)
1.62
2.35
5.82
2.08
2.33
Diluted Shares Outstanding
1,247.70
1,710.10
2,203.40
3,978.70
4,672.20
EBITDA
1,943.20
3,507.80
2,229.40
5,275.00
8,770.40
Non-Operating Interest Income
14.00
38.30
42.40
122.00
74.00

About VioQuest Pharmaceuticals

View Profile
Address
180 Mount Airy Road
Basking Ridge New Jersey 07920
United States
Employees -
Website -
Updated 07/08/2019
Develops early clinical-stage therapies for metabolic, inflammatory diseases and cancer .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.